BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2018

View Archived Issues

MALAT: unfairly accused of promoting metastasis?

Read More

Adaptive and innate immunity is two-way street

Read More

LY-3358966 potently inhibits intestinal phosphate absorption in animal models

Read More

New compound GDT-01 improves diabetic nephropathy in ZSF1 rats

Read More

Bispecific radioimmunoconjugates tested in novel tumor model heterogeneous for HER2 and EGFR

Read More

Peptoid-peptide hybrids targeting beta-catenin:TCF interaction show utility in PCa models

Read More

Researchers develop the first conditional Fxr2 knockout models of fragile X syndrome

Read More

Genetic variants in CD274 increase risk of Fuchs endothelial corneal dystrophy in smokers

Read More

L.E.A.F. receives pre-IND feedback from FDA for four anticancer drugs

Read More

Clotting protein could be targeted in neurodegeneration

Read More

First patient enrolled in phase II study of ANAVEX2-73 for the treatment of PDD

Read More

Mirvetuximab soravtansine combined with pembrolizumab is effective in ovarian cancer

Read More

Positive long-term data presented from pivotal phase III AMBER study of Symtuza

Read More

G2-S16 proves to be safe and effective topical vaginal microbicide against HIV in vivo

Read More

Patient enrollment ongoing in phase I study of ADG-106

Read More

Preliminary data presented from first-in-human phase I/IIa study of CAN-04

Read More

Pilot study evaluates 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine neoplasms

Read More

Scancell updates development of Modi-2 for multiple solid tumors

Read More

FDA approves Keytruda with chemotherapy for first-line metastatic squamous NSCLC

Read More

InflaRx studies IFX-1 for ANCA-associated vasculitis in phase II

Read More

IRLAB offers analysis on phase IIa results of IRL-752 in Parkinson's disease

Read More

Aura reports updated results from phase Ib/II trial of AU-011 in choroidal melanoma

Read More

Distributed Bio collaborates with H3 Biomedicine to discover novel cancer therapeutics

Read More

FDA approves Invokana to reduce risk of CV events in adults with type 2 diabetes and CV disease

Read More

Trial results suggest Alzheimer's disease modification with BAN-2401

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing